Article
Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα-2a.
Digestive diseases (Basel, Switzerland) - 1 Jan 2012
Hagiwara Satoru, Sakurai Toshiharu, Takita Masahiro, Ueshima Kazuomi, Minami Yasunori, Inoue Tatsuo, Yada Norihisa, Kitai Satoshi, Nagai Tomoyuki, Hayaishi Sousuke, Arizumi Tadaaki, Nishida Naoshi, Kudo Masatoshi
Abstract excerpt
OBJECTIVE: Increasing evidence suggests the efficacy of maintenance therapy with interferon (IFN) for chronic hepatitis C (CHC) in reducing the risk of hepatocellular carcinoma (HCC). The aim of this study was to determine clinical characteristics on the risk of occurrence of HCC in CHC patients receiving maintenance IFN therapy. METHODS: A total of 55 patients were treated in a single center with PEG-IFNα-2a...
Topics
- Adult
- Aged
- Alanine Transaminase
- Antiviral Agents
- Body Mass Index
- Carcinoma, Hepatocellular
- Female
- Hepatitis C, Chronic
- Humans
- Interferon-alpha